San Diego, CA, United States of America

James M Frincke

This inventor holds 25 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Steroid Pharmaceuticals. Top assignees: Harbor Biosciences, Inc., Harbor Therapeutics, Inc., Hollis-Eden Pharmaceuticals, Inc.. Active years: 2009-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James M Frincke. Retrieved from https://idiyas.com/inventor/james-m-frincke

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 25 

% Patents Active = 12.0


 

Average Co-Inventor Count = 1.2

ph-index = 8

Forward Citations = 186(Granted Patents)


Location History:

  • Carlsbad, CA (US) (2009 - 2013)
  • San Diego, CA (US) (2009 - 2015)

Company Filing History:


Years Active: 2009-2015

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Steroids
Pharmaceutical Compositions
Cancer Treatment
Drug Screening
Cystic Fibrosis
Sepsis Treatment
Stem Cell Expansion
Therapeutic Methods
Tetrol Steroids
Compounds
Formulations
Drug Identification
25 patents (USPTO):Explore Patents

Title: James M Frincke: Innovator in Steroidal Compounds for Treating Conditions

Introduction:

James M Frincke is an eminent inventor and researcher in the field of pharmaceuticals and is known for his groundbreaking work in developing steroidal compounds to ameliorate or treat conditions such as cystic fibrosis and neutropenia. With an impressive portfolio of 25 patents to his name, Frincke has made significant contributions to the medical field, particularly in the area of steroid-based therapeutics.

Latest Patents:

Among his notable patents, two recent inventions stand out: Steroids having 7-oxygen and 17-heteroaryl substitution-3 and Steroids having 7-oxygen and 17-heteroaryl substitution-2. These patents cover the use of various compounds, including 7β-hydroxy-17-(3-pyridyl)-androst-4,16-diene-3-one and 3β,7β-dihydroxy-17-(3-pyridyl)-androst-5,16-diene, for the treatment of several conditions, including cystic fibrosis and neutropenia. These inventions showcase Frincke's expertise in the development of innovative solutions for critical medical needs.

Career Highlights:

Throughout his illustrious career, James M Frincke has collaborated with renowned companies in the pharmaceutical industry to further his research and bring his innovations to market. Frincke has notably worked with Harbor Biosciences, Inc. and Harbor Therapeutics, Inc., where he has contributed significantly to the advancement of pharmaceutical treatments. His patents reflect the extensive knowledge and dedication he has brought to his collaborations, demonstrating his expertise in developing novel compounds to address unmet medical needs.

Collaborations:

James M Frincke has had the opportunity to work alongside accomplished professionals in his field, including Christopher Reading and Clarence Nathaniel Ahlem. Collaborations such as these facilitate the exchange of ideas and expertise, pushing the boundaries of innovation in pharmaceutical research. Through working with skilled colleagues, Frincke has been able to enhance his own research endeavors and yield groundbreaking results.

Conclusion:

With an impressive patent portfolio and a string of successful collaborations with notable organizations, James M Frincke has established himself as a leading figure in the field of steroidal compounds for treating various medical conditions. His dedication to advancing pharmaceutical research and his innovative thinking have paved the way for improved therapeutic options. Frincke's contributions underline the importance of intellectual property protection in fostering innovation and improving lives through advancements in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…